Coating calcifications

How Inositec aims to treat vascular calcification in CKD patients

Inositec AG aims to halt vascular calcification in patients with chronic kidney disease by making analogs of the calcium chelator inositol hexaphosphate that are safer and more drug-like than the natural product.

According to co-founder and CEO Mattias Ivarsson, research over the last 10 years has linked poor CV outcomes in the chronic kidney disease (CKD) population to development of vascular calcification, a process that occurs when high concentrations of calcium phosphate in the blood trigger formation of

Read the full 785 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE